Interreg

Deutschland-Nederland

InMediValue

Innovation in medical imaging value chains

The project includes:
– the development of a pain-reduced 3D mammography examination procedure to achieve a higher quality and participation rate in breast cancer screening
– the development of artificial intelligence-based technology for 3D mammography image analysis to improve the analysis of calcium deposition patterns in radiological reporting and
– the development of a multimodal imaging marker to enable surgeons to localize involved lymph nodes or tumors using innovative imaging techniques.

Demandoriented, practical problems from the field of medical imaging, e.g. from the university hospital (user), are to be addressed in order to develop solutions in cooperation with the universities and the companies involved. The participating research institutions and companies develop and protect innovative solutions and findings in order to be able to offer them in the short, medium and long term for the benefit of patients. In addition, the products of the participating companies currently being developed are to be brought to market maturity and made accessible across borders for the performance and evaluation of mammography examinations.

Project
Information

Planned project

3.437.839,94 €

Project Duration

1.10.2018 - 30.9.2021

Priority

Erhöhung der grenzüberschreitenden Innovationskraft im Programmgebiet

Lead Partner

Fachhochschule Münster

Project partners

TAFH Münster GmbH, Cysal GmbH, Sigmascreening BV, ScreenPoint Medical BV, MIRA-Institut, Universität Twente, Institut für Klinische Radiologie

Project
Financing

Financer Amount
TAFH Münster GmbH 0,00 €
Provincie Gelderland 40.655,80 €
Cysal GmbH 58.399,00 €
MIRA-Institut, Universität Twente 59.540,00 €
Provincie Overijssel 81.311,60 €
Institut für Klinische Radiologie 94.463,00 €
Ministerie van Economische Zaken en Klimaat 182.951,00 €
Fachhochschule Münster 264.088,54 €
ScreenPoint Medical BV 304.144,00 €
MWIDE NRW 304.918,00 €
Sigmascreening BV 328.450,00 €
EFRE / EFRO 1.718.919,00 €